United Therapeutics Corporation Net Assets
United Therapeutics Corporation net assets. Based on the latest financial reports, United Therapeutics Corporation (UTHR) has net assets worth $6.40 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.22 Billion) and total liabilities ($819.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore United Therapeutics Corporation net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.40 Billion |
| % of Total Assets | 88.65% |
| Annual Growth Rate | 25.12% |
| 5-Year Change | 79.25% |
| 10-Year Change | 281.07% |
| Growth Volatility | 73.4 |
Net Assets of United Therapeutics Corporation (1998–2025)
Net assets of United Therapeutics Corporation from 1998 to 2025. This chart illustrates how United Therapeutics Corporation's net assets have evolved over time, based on quarterly financial data. See UTHR equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for United Therapeutics Corporation (1998–2025)
The table below shows the annual net assets of United Therapeutics Corporation from 1998 to 2025. For live market cap and overall valuation, see UTHR market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $7.10 Billion | +10.12% |
| 2024-12-31 | $6.44 Billion | +7.67% |
| 2023-12-31 | $5.98 Billion | +24.77% |
| 2022-12-31 | $4.80 Billion | +21.16% |
| 2021-12-31 | $3.96 Billion | +16.60% |
| 2020-12-31 | $3.40 Billion | +22.11% |
| 2019-12-31 | $2.78 Billion | -0.29% |
| 2018-12-31 | $2.79 Billion | +32.68% |
| 2017-12-31 | $2.10 Billion | +12.87% |
| 2016-12-31 | $1.86 Billion | +16.41% |
| 2015-12-31 | $1.60 Billion | +26.40% |
| 2014-12-31 | $1.27 Billion | -2.97% |
| 2013-12-31 | $1.30 Billion | +19.13% |
| 2012-12-31 | $1.09 Billion | +15.43% |
| 2011-12-31 | $948.49 Million | +7.31% |
| 2010-12-31 | $883.89 Million | +35.36% |
| 2009-12-31 | $653.01 Million | +28.62% |
| 2008-12-31 | $507.70 Million | +71.64% |
| 2007-12-31 | $295.79 Million | +44.57% |
| 2006-12-31 | $204.61 Million | -25.63% |
| 2005-12-31 | $275.10 Million | +43.55% |
| 2004-12-31 | $191.64 Million | +14.23% |
| 2003-12-31 | $167.76 Million | -2.27% |
| 2002-12-31 | $171.66 Million | -12.60% |
| 2001-12-31 | $196.40 Million | -16.33% |
| 2000-12-31 | $234.74 Million | +337.94% |
| 1999-12-31 | $53.60 Million | +220.96% |
| 1998-12-31 | $16.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to United Therapeutics Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 857270000000.0% over the analyzed period, indicating profitable operations and earnings retention.
United Therapeutics Corporation Net Assets Breakdown (December 2025)
United Therapeutics Corporation net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $8.56 Billion | 120.58% |
| Common Stock | $800.00K | 0.01% |
| Other Comprehensive Income | $900.00K | 0.01% |
| Total Equity | $7.10 Billion | 100.00% |
United Therapeutics Corporation Competitors by Market Cap
The table below lists competitors of United Therapeutics Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hindalco Industries Limited
NSE:HINDALCO
|
$21.39 Billion |
|
Coca-Cola Femsa SAB de CV ADR
NYSE:KOF
|
$21.39 Billion |
|
Eicher Motors Limited
NSE:EICHERMOT
|
$21.42 Billion |
|
International Flavors & Fragrances Inc
NYSE:IFF
|
$21.45 Billion |
|
Baidu Inc
NASDAQ:BIDU
|
$21.26 Billion |
|
Santos Ltd
AU:STO
|
$21.26 Billion |
|
Kuehne & Nagel
SW:KNIN
|
$21.22 Billion |
|
Equifax Inc
NYSE:EFX
|
$21.21 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in United Therapeutics Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,444,000,000 to 7,096,200,000, a change of 652,200,000 (10.1%).
- Net income of 1,334,700,000 contributed positively to equity growth.
- Share repurchases of 1,000,000,000 reduced equity.
- Other comprehensive income increased equity by 4,300,000.
- Other factors increased equity by 313,200,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.33 Billion | +18.81% |
| Share Repurchases | $1.00 Billion | -14.09% |
| Other Comprehensive Income | $4.30 Million | +0.06% |
| Other Changes | $313.20 Million | +4.41% |
| Total Change | $- | 10.12% |
Book Value vs Market Value Analysis
This analysis compares United Therapeutics Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.04x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 596.71x to 4.04x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $1.00 | $598.72 | x |
| 1999-12-31 | $2.01 | $598.72 | x |
| 2000-12-31 | $6.10 | $598.72 | x |
| 2001-12-31 | $4.84 | $598.72 | x |
| 2002-12-31 | $4.16 | $598.72 | x |
| 2003-12-31 | $3.97 | $598.72 | x |
| 2004-12-31 | $4.10 | $598.72 | x |
| 2005-12-31 | $5.46 | $598.72 | x |
| 2006-12-31 | $4.24 | $598.72 | x |
| 2007-12-31 | $6.59 | $598.72 | x |
| 2008-12-31 | $11.08 | $598.72 | x |
| 2009-12-31 | $11.63 | $598.72 | x |
| 2010-12-31 | $14.85 | $598.72 | x |
| 2011-12-31 | $15.97 | $598.72 | x |
| 2012-12-31 | $20.55 | $598.72 | x |
| 2013-12-31 | $24.50 | $598.72 | x |
| 2014-12-31 | $23.37 | $598.72 | x |
| 2015-12-31 | $31.23 | $598.72 | x |
| 2016-12-31 | $39.79 | $598.72 | x |
| 2017-12-31 | $46.81 | $598.72 | x |
| 2018-12-31 | $63.38 | $598.72 | x |
| 2019-12-31 | $63.48 | $598.72 | x |
| 2020-12-31 | $76.13 | $598.72 | x |
| 2021-12-31 | $83.70 | $598.72 | x |
| 2022-12-31 | $98.90 | $598.72 | x |
| 2023-12-31 | $120.42 | $598.72 | x |
| 2024-12-31 | $132.87 | $598.72 | x |
| 2025-12-31 | $148.15 | $598.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently United Therapeutics Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.81%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 41.94%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.11x
- Recent ROE (18.81%) is above the historical average (6.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -76.65% | -12800.00% | 0.01x | 1.12x | $-14.47 Million |
| 1999 | -62.50% | -8375.00% | 0.01x | 1.12x | $-38.86 Million |
| 2000 | -32.21% | -3689.55% | 0.01x | 1.07x | $-99.08 Million |
| 2001 | -18.99% | -650.55% | 0.03x | 1.08x | $-56.93 Million |
| 2002 | -13.78% | -78.52% | 0.16x | 1.08x | $-40.82 Million |
| 2003 | -5.94% | -18.69% | 0.30x | 1.07x | $-26.75 Million |
| 2004 | 8.06% | 20.99% | 0.36x | 1.08x | $-3.71 Million |
| 2005 | 23.63% | 56.09% | 0.40x | 1.06x | $37.51 Million |
| 2006 | 36.15% | 46.33% | 0.33x | 2.34x | $53.50 Million |
| 2007 | 6.71% | 9.41% | 0.36x | 1.98x | $-9.72 Million |
| 2008 | -8.43% | -15.20% | 0.32x | 1.72x | $-93.56 Million |
| 2009 | 2.98% | 5.26% | 0.35x | 1.61x | $-45.84 Million |
| 2010 | 11.98% | 17.54% | 0.42x | 1.62x | $17.53 Million |
| 2011 | 22.97% | 29.32% | 0.49x | 1.60x | $123.02 Million |
| 2012 | 27.81% | 33.23% | 0.56x | 1.49x | $194.96 Million |
| 2013 | 13.38% | 15.63% | 0.54x | 1.60x | $44.13 Million |
| 2014 | 26.87% | 26.39% | 0.68x | 1.49x | $213.52 Million |
| 2015 | 40.74% | 44.46% | 0.67x | 1.37x | $491.67 Million |
| 2016 | 38.33% | 44.64% | 0.69x | 1.25x | $527.48 Million |
| 2017 | 19.88% | 24.22% | 0.60x | 1.37x | $207.72 Million |
| 2018 | 21.13% | 36.20% | 0.48x | 1.22x | $310.34 Million |
| 2019 | -3.76% | -7.21% | 0.37x | 1.41x | $-382.54 Million |
| 2020 | 15.16% | 34.71% | 0.32x | 1.36x | $175.28 Million |
| 2021 | 12.02% | 28.23% | 0.33x | 1.31x | $79.91 Million |
| 2022 | 15.16% | 37.56% | 0.32x | 1.26x | $247.63 Million |
| 2023 | 16.46% | 42.31% | 0.32x | 1.20x | $386.32 Million |
| 2024 | 18.55% | 41.53% | 0.39x | 1.14x | $550.70 Million |
| 2025 | 18.81% | 41.94% | 0.40x | 1.11x | $625.08 Million |
Industry Comparison
This section compares United Therapeutics Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $100,165,415
- Average return on equity (ROE) among peers: -25.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $6.40 Billion | -76.65% | 0.13x | $21.32 Billion |
| Aurora Cannabis Inc (ACB) | $1.71 Million | -2.57% | 0.01x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $166.09 Million | -138.50% | 2.72x | $143.73 Million |
| Akanda Corp (AKAN) | $-11.99 Million | 0.00% | 0.00x | $562.47K |
| Akebia Ther (AKBA) | $131.00 Million | -46.35% | 0.09x | $189.26 Million |
| Alkermes Plc (ALKS) | $161.37 Million | -10.45% | 1.50x | $7.61 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $3.22 Billion |
| Amphastar P (AMPH) | $329.25 Million | 3.20% | 0.30x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $208.93 Million | -62.22% | 17.18x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-44.54 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $85.19 Million | 5.07% | 0.51x | $279.44 Million |
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil)… Read more